SEC Tracker
Get the app

Rapport Therapeutics RAPP

Rapp Therapeutics closes $215.7M stock offering

Item 1.01 Enters material agreement

Form
8-K
Filed
Importance
Major
  1. Raised $215.7M net proceeds from stock and pre-funded warrants
  2. Offering included 8,333,334 shares and 1,190,476 pre-funded warrants
  3. Underwriters exercised full option to buy 1,428,571 additional shares

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Rapport Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

  1. The company entered into the agreement with Morgan Stanley & Co. LLC, Leerink Partners LLC, and Evercore Group L.L.C. as representatives of the underwriters.
  2. The offering included 8,333,334 shares of common stock and pre-funded warrants for up to 1,190,476 shares.
  3. The offering price for each share was $21.00, and each pre-funded warrant was sold at $20.999.
  4. The underwriters exercised their option to purchase an additional 1,428,571 shares.
  5. The pre-funded warrants have an initial exercise price of $0.001 per share and are exercisable immediately.

5 of 5 claims matched the filing text.

For perspective, checked against its own source

From the 10-Q for the quarter ended June 30, 2026

  • For the quarter ended June 30, 2026, Rapport Therapeutics reported revenue of $0 and a net loss of $56.6 million.

From the filing

Item 1.01 Entry into a Material Definitive Agreement.

Item 1.01 Entry into a Material Definitive Agreement.

Underwriting Agreement in Respect of Common Stock and Pre-Funded Warrants

On October 28, 2026, Rapport Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Equity Underwriting Agreement") with Morgan Stanley & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C. as representatives of the several underwriters1 (collectively, the "Equity Offering Underwriters"), related to an underwritten public offering (the "Common Stock Offering") of (i) 8,333,334 shares (the "Firm Shares") of the Company's common stock, par value $0.001 per share ("Common Stock") and (ii) in lieu of Common Stock to certain investors, pre-funded warrants to purchase an aggregate of up to 1,190,476 shares of Common Stock2 (the "Pre-Funded Warrants" and the Common Stock issuable upon exercise of the Pre-Funded Warrants, the "Pre-Funded Warrant Shares"). In addition, the Company has granted the Equity Offering Underwriters an option, exercisable in whole or in part at any time for a period of 30 days from the date of the Underwriting Agreement, to purchase, at the offering price, less the underwriting discounts and commissions, up to an additional 1,428,571 shares of Common Stock (the "Option Shares," and, together with the Firm Shares, the "Shares"). Each Share was offered and sold at a public offering price of $21.00 (the "Offering Price"), and each Pre-Funded Warrant was offered and sold at a public offering price of $20.9993, which is equal to the Offering Price less the $0.001 exercise price of each Pre-Funded Warrant. On October 28, 2026, the Equity Offering Underwriters exercised their option in full to purchase 1,428,571 Option Shares4.

Each Pre-Funded Warrant has an initial exercise price per share of $0.001, subject to certain adjustments.5 5The Pre-Funded Warrants are exercisable immediately5 and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. Under the Pre-Funded Warrants,

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  2. Ocugen OCGN public float $279M, Jun 30, 2025
  3. Tonix Pharmaceuticals Holding TNXP public float $271M, Jun 30, 2025
  4. Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025
  5. Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025